Chime Biologics won two awards at the Asia Pacific Biologics CMO Excellence Awards 2024
Recently, at the 3rd Biologics Contract Manufacturing Asia held in Singapore, Chime Biologics was honored with two prestigious awards at the Asia Pacific Biologics CMO Excellence Awards (APBCEA) 2024 — “Best CDMO Award of the Year” and “Best Biologics CMO Award: Analytical Services.”
Mr. James Huang, Executive Chairman of Chime Biologics (right), accepted the awards on behalf of the company at the ceremony held on September 10th.
Best CDMO Award of the Year
Best Biologics CMO Award: Analytical Services
Chime Biologics Offers Comprehensive Analytical Testing Services
Chime Biologics provides a full range of analytical services, including method development, validation, and verification, as well as comprehensive testing from drug development to commercialization, ensuring product quality meets international standards. The analytical testing team at Chime Biologics utilizes advanced analytical technologies to provide customized solutions, accelerating the transformation of products from research and development to the market.
As a leading global CDMO, Chime Biologics offers one-stop services from preclinical research to commercialization, meeting the biopharmaceutical manufacturing needs at various scales and stages, ensuring that our global clients’ products can enter the market efficiently and safely.
Mr. James Huang, Executive Chairman of Chime Biologics, said, “I am delighted to represent Chime Biologics in receiving these two awards in Singapore. This is not only a recognition of Chime Biologics’ contributions in the field of biopharmaceutical CDMO but also an affirmation of our specialized technical expertise. These achievements are key factors in our ability to gain customer recognition in the biopharmaceutical industry across the Asia Pacific region and globally.”
About Chime Biologics
Chime Biologics is a global leading CDMO that has introduced the first modular biopharmaceutical plant KUBio in the world to empower its partners’ success in biologics in the whole process from cell line development to commercial manufacturing. Relying on cell line development and advanced technology development from our Shanghai Innovation Center and proven success in IND-enabling through BLA filing at its Wuhan plant, Chime Biologics is providing a one-stop CMC solution for biopharmaceutical customers around the world. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling its commitment to human health. For more information, please visit: www.chimebiologics.com.
